References
- Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005 Nov;98(11):829–836.
- Miles KA, Packer C, Stevens A. Quantifying emerging drugs for very rare conditions. QJM. 2007 May;100(5):291–295.
- McCabe C, Tsuchiya A, Claxton K, et al. Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al. Int J Technol Assess Health Care. 2007 Summer;23(3):397–401; author reply 401–4.
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007 Winter;23(1):36–42.
- UK-Gov. How UK orphan medicinal products will be managed in a no deal scenario; 2019 [cited 2020 May 29]. Available from: https://www.gov.uk/guidance/how-uk-orphan-medicinal-products-will-be-managed-in-a-no-deal-scenario
- Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ. 2005 Oct 29;331(7523):1019–1021.
- Martin J. Expensive drugs for rare diseases. [cited 2020 May 29]. Available from: https://www.cadth.ca/media/symposium_pdfs/cadth_symposium06_ppt_Martin2.pdf
- Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet J Rare Dis. 2013 Nov 16;8:180. .
- de Sola-morales O. Funding orphan medicinal products beyond price: sustaining an ecosystem. Eur J Health Econ. 2019 Dec;20(9):1283–1286.
- Lally C, Jones C, Farwell W, et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet J Rare Dis. 2017 Nov 28;12(1):175.
- Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017 Mar;81(3):355–368.
- Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015 Jun 10;35(23):8691–8700.
- Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007 Aug;22(8):1027–1049.
- Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb 01;28(2):103–115.
- Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar 01;28(3):197–207.
- Bach JR, Is Noninvasive POINT. Ventilation always the most appropriate manner of long-term ventilation for infants with spinal muscular atrophy Type 1? Yes, almost always. Chest. 2017 May;151(5):962–965.
- Panitch HB. COUNTERPOINT: is noninvasive ventilation always the most appropriate manner of long-term ventilation for infants with spinal muscular atrophy Type 1? No. Chest. 2017 May;151(5):965–968.
- Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020 Feb 11;21(3):307–315.
- Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017 oct 03;17(10):955–962.
- [cited 2020 May 29]. Available from: https://pharmaintelligence.informa.com/resources/product-content/novartis-pharma-ceo-sees-zolgensma-supplanting-spinraza
- Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.
- Chiou M, Bach JR, Goncalves MR. Poster 206 determinants of continuous noninvasive ventilatory support outcomes. Pm R. 2016 Sep;8(9S):S228.
- Cadth common drug review pharmacoeconomic report for nusinersen. 2018, p. 83.
- Burgart AM, Magnus D, Tabor HK, et al. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. 2018 Feb 1;172(2):188–192.
- NICE NIfHaCE. Nusinersen for treating spinal muscular atrophy.ID1069 committee papers. 2018. Available from: https://nice.org.uk/guidance/indevelopment/gid-ta10281/documents
- Zuluaga-Sanchez S, Teynor M, Knight C, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019 Jun;37(6):845–865.
- Lopez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, et al. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017 Aug 18;12(1):141.
- OECD. [cited 2020 May 29]. Available from: https://www.oecd.org › sdd › prices-ppp
- Garber AM, Soloman NA. Cost-Effectiveness of Alternative Test Strategies for the Diagnosis of Coronary Artery Disease. Ann Internal Med. 1999;130(9):719–728.
- Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3 ed. Oxford: Oxford Univbersity Press; 2005.
- Morris S, Devlin N, Parkin D, et al. Economic analysis in health care. 2 ed. Wiley: Chichester, UK; 2012.
- Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017 Jul 4;12(1):124.
- Gallacher D, Achana F. Assessing the health economic agreement of different data sources. Stata J. 2018;18(1):223–233.
- Alexandersson A. Graphing confidence ellipses: an update of ellip for Stata 8. Stata J. 2004;4(3):242–256.
- Wood EM, Hughes DA, New T. Non-transparent cancer drugs fund. Pharmacoeconomics. 2020 Jan;38(1):1–4.
- Elek P, Takacs E, Meresz G, et al. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy Plan. 2017 Apr 1;32(3):349–358.
- Kanavos P, Fontrier A, Gill J, et al. The impact of external reference pricing within and across countries 2017 [cited]. London School of Economics, London.
- Rare-disease-commissioning-group. [cited 2020 May 29]. Available from: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/09/rdag-tor-aug-16.pdf
- House-of-Commons. Hansard ministerial statements for 08 october: written ministerial statements; health; paroxysmal nocturnal haemoglobinuria. 2008 Oct 8 [cited 2020 May 29]. Available from: https://publications.parliament.uk/pa/cm200708/cmhansrd/cm081008/wmstext/81008m0001.htm
- Griffiths R. 2009 [cited 2020 May 29]. Available from: https://publications.parliament.uk/pa/cm200809/cmselect/cmhealth/1020/1020w207.htm
- Cohen JP, Felix A. Are payers treating orphan drugs differently? J Mark Access Health Policy. 2014. https://www.ncbi.nlm.nih.gov/pubmed/27226840. 2014/01/01 ed2014
- 2019 [cited 2020 May 29]. Available from: https://www.reuters.com/article/us-novartis-genetherapy-death/second-death-in-novartis-gene-therapy-trials-under-investigation-idUSKCN1RW005
- White W. A rare disease patient/caregiver perspective on fair pricing and access to gene-based therapies. Gene Ther. 2019 nov 13. DOI:10.1038/s41434-019-0110-7